AZ Looks To Lead Severe Asthma Market After US Fasenra OK

Following FDA approval, AstraZeneca believes that despite reaching the market after GlaxoSmithKline’s Nucala and Teva’s Cinqair, Fasenra's strong clinical package, convenient dosing and very competitive pricing will make it the leading biologic for severe asthma.

Speedway
AstraZeneca joins the severe asthma race with the US approval of Fasenra • Source: Shutterstock

Days after getting a recommendation for approval in Europe, AstraZeneca PLC has been given the green light in the US to market Fasenra (benralizumab) as a treatment for severe asthma and an alternative to GlaxoSmithKline PLC’s Nucala (mepolizumab) and Teva Pharmaceutical Industries Ltd.'s Cinqair (respizumab).

Specifically, the US Food and Drug Administration has approved Fasenra for the add-on maintenance treatment of patients with severe asthma...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Respiratory

More from Therapeutic Category